Adamo, Vincenzo http://orcid.org/0000-0003-2074-2418
Antonuzzo, Lorenzo http://orcid.org/0000-0003-3349-5604
Danova, Marco
De Laurentiis, Michelino http://orcid.org/0000-0001-9009-1572
Marchetti, Paolo http://orcid.org/0000-0002-9064-8761
Pinto, Carmine http://orcid.org/0000-0002-3159-5268
Rosti, Giovanni http://orcid.org/0000-0003-2097-2803
Article History
Received: 12 April 2022
Accepted: 23 October 2022
First Online: 5 November 2022
Declarations
:
: This consensus study was approved by the review boards of the institutions of all scientific board members.
: Informed consent to participate was obtained from the survey panel. The experts were informed that the survey results would be anonymised prior to discussion by the scientific board.
: Informed consent for the results of the study to be published was obtained from the survey panel.
: Vincenzo Adamo, during the past 3 years, received honoraria for consultant roles and/or participation in advisory boards and/or meetings by Amgen, AstraZeneca, BMS, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, Sevier, and Takeda, outside of the submitted work.Marco Danova has received personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Accademia Nazionale di Medicina, AstraZeneca, Novartis, Roche, Sandoz, and Servier, outside of the submitted work. Michelino De Laurentiis has received personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Exact Science, Eli Lilly, Gilead, Ipsen, Merck Sharp and Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and Seagen, outside of the submitted work. Paolo Marchetti has received research funding from Roche, Merck Sharp and Dohme, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Novartis, and Pfizer and personal fees from Roche, Merck Sharp and Dohme, Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer. Carmine Pinto has received personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Clovis Oncology, Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp and Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier, outside of the submitted work. Lorenzo Antonuzzo and Giovanni Rosti have no competing interests to declare that are relevant to the content of this article.